Oppenheimer & Co. Inc. Has $4.78 Million Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Oppenheimer & Co. Inc. lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.7% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 65,894 shares of the medical research company's stock after purchasing an additional 5,853 shares during the quarter. Oppenheimer & Co. Inc.'s holdings in Edwards Lifesciences were worth $4,776,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Vega Investment Solutions acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $27,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $29,000. Global X Japan Co. Ltd. lifted its position in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares in the last quarter. Finally, ORG Wealth Partners LLC acquired a new position in Edwards Lifesciences during the 1st quarter worth approximately $38,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on EW shares. Truist Financial reduced their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Citigroup reissued a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Finally, Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $80.20.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider now directly owns 206,900 shares of the company's stock, valued at $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the transaction, the vice president now directly owns 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,648 shares of company stock valued at $2,998,866. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.22 during trading on Thursday, hitting $77.19. 4,814,245 shares of the stock were exchanged, compared to its average volume of 5,247,201. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $95.25. The stock's fifty day moving average is $75.38 and its 200 day moving average is $73.08. The stock has a market cap of $45.28 billion, a PE ratio of 11.03, a P/E/G ratio of 3.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the business earned $0.66 earnings per share. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.